A Study Of TL-925 For The Treatment of AC
In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 70 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally.

The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.
- EligibilityCriteria: Inclusion Criteria:  Individuals aged 18 years or older Female subjects of childbearing potential and their male partners must both use a highly effective contraception method during the study. Documented history of ocular allergies and a positive skin test reaction to a seasonal (grass, ragweed, tree pollen) or perennial (cat dander, dog dander, dust mites, cockroach) allergen as confirmed by an allergic skin test conducted at Visit 1 or within the past 60 months. Calculated best-corrected visual activity of 0.7 LogMAR or better Positive bilateral CAC reaction  Exclusion Criteria:  Any systemic or ocular disease currently producing ocular redness and/or ocular discomfort, or that may interfere with the conduct of the study. Any ocular surgical intervention within the last 3 months OR refractive surgery within the last 6 months Any ongoing ocular infection (bacterial, viral or fungal) - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult